These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 15788688)
1. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688 [TBL] [Abstract][Full Text] [Related]
2. [Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma]. Zhang G; Zhao M; Xu M; Yang Y; Wang M; Yang C Zhonghua Jie He He Hu Xi Za Zhi; 2002 Feb; 25(2):89-93. PubMed ID: 11953105 [TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
4. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244 [TBL] [Abstract][Full Text] [Related]
5. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Zhou Z; Bolontrade MF; Reddy K; Duan X; Guan H; Yu L; Hicklin DJ; Kleinerman ES Clin Cancer Res; 2007 Aug; 13(16):4867-73. PubMed ID: 17699866 [TBL] [Abstract][Full Text] [Related]
9. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Zhou Z; Reddy K; Guan H; Kleinerman ES Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258 [TBL] [Abstract][Full Text] [Related]
10. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Ng IO; Poon RT; Lee JM; Fan ST; Ng M; Tso WK Am J Clin Pathol; 2001 Dec; 116(6):838-45. PubMed ID: 11764072 [TBL] [Abstract][Full Text] [Related]
11. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299 [TBL] [Abstract][Full Text] [Related]
12. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647 [TBL] [Abstract][Full Text] [Related]
13. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346 [TBL] [Abstract][Full Text] [Related]
14. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116 [TBL] [Abstract][Full Text] [Related]
17. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856 [TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. Forooghian F; Das B Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204 [TBL] [Abstract][Full Text] [Related]
20. Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Hara H; Akisue T; Fujimoto T; Imabori M; Kawamoto T; Kuroda R; Fujioka H; Yamamoto T; Doita M; Kurosaka M Anticancer Res; 2006; 26(6B):4307-11. PubMed ID: 17201149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]